Japan and Singapore forge biomaterials deal:
This article was originally published in Clinica
Executive Summary
The Japanese National Institute for Materials Science and the National University of Singapore last month signed memorandum to collaborate in the field of biomaterials research. Under the agreement, both sides will exchange information and share technology for the designing and processing of biomaterials. The aim is to commercialise new products for advanced medical treatment. The memorandum is part of the Japan-Singapore Economic Agreement, concluded in January 2002, contained within the New Age Partnership, which also includes a bilateral trade agreement, reports Japan Chemical Week.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.